| CURRICULUM
VITAE-
PRESENT POSITION
AND ADDRESS:
07/02 Present Professor
and Chairman, Department of Neurology
John
Sealy Chair in Neurology
The
University of Texas Medical Branch
301
University Boulevard, JSA 9.128
Galveston, Texas 77555-0539
Phone: (409)
772-2466
Fax: (409)
772-2390
E-mail: teashiza@utmb.edu
BIOGRAPHICAL: Date
of Birth September
11,1948
Place
of Birth Tokyo,
Japan
Citizenship Japan,
U.S. Permanent Resident
Home
Address 4300
Bay Area Blvd, #3527, Houston, Texas 77058
EDUCATION:
04/67-03/69 Premed Keio University Premed. School, Kanagawa, Japan
04/69-03/73 M.D. Keio University School of Medicine,
Tokyo, Japan
04/73-03/74 Rotating
Intern U.S.
Naval Regional Med. Center, Yokosuka, Japan
07/74-06/75 Intern
(Int. Med.) Allegheny
General Hospital, Pittsburgh, PA
07/75-02/78 Resident
(Neurology) Baylor College of Medicine, Houston, TX
03/78-06/79 Fellow
(Neuromuscular) Baylor College of Medicine, Houston, TX
07/79-06/81 Fellow
(Neurochemistry) Baylor College of Medicine, Houston, TX
PROFESSIONAL
AND TEACHING EXPERIENCE:
07/02-present Professor
and Chairman, John Sealy Chair in Neurology, Department of Neurology,
The University of Texas Medical Branch, Galveston, TX
10/02-present Member,
Graduate Faculty, Department of Neurosciences, The University
of Texas Medical Branch Graduate School of Biomedical Sciences
at Galveston.
10/02-present Adjunct
Professor, Department of Neurology, Baylor College of Medicine
12/97-06/02 Professor
in Neurology, Baylor College of Medicine, Houston, TX
09/92-11/97 Associate
Professor in Neurology, Baylor College of Medicine, Houston, TX
07/94-06/96 Director
of Student and Residency Program, Department of Neurology, Baylor
College of Medicine, Houston, TX
07/88-07/02 Assistant
Chief of Neurology Service and Deputy Executive of Neurology
Care Line, VA Medical Center, Houston, TX
03/93-02/94 Visiting
scientist, Laboratory of Dr. C. Thomas Caskey, Department of
Human and Molecular Genetics, Baylor College of Medicine (sabbatical
leave), Houston, TX
01/88-06/88 Acting
Chief, Neurology Service, VA Medical Center, Houston, TX
03/85-01/88 Assistant
Chief, Neurology Service, VA Medical Center, Houston, TX
07/81-08/92 Assistant
Professor in Neurology, Baylor College of Medicine, Houston, TX
07/79-06/81 Muscular
Dystrophy Association Research Fellow, Baylor College of Medicine, Houston, TX
07/78-06/79 Muscular
Dystrophy Association Clinical Fellow, Baylor College of Medicine,
Houston, TX
03/78-06/78 Chief
Resident in Neurology, Baylor College of Medicine, Houston, TX
07/75-02/78 Resident
in Neurology, Baylor College of Medicine, Houston, TX
07/74-06/75 Medical
Intern, Allegheny General Hospital, Pittsburgh, Pennsylvania
04/74-06/74 Medical
Resident, Kitasato University Hospital, Kanagawa, Japan
04/73-03/74 Rotating
Intern, U.S. Naval Regional Medical Center, Yokosuka, Japan
RESEARCH ACTIVITIES:
A. Area
of Research
Spinocerebellar
ataxia type 10. (NIH.)
We
postulate that spinocerebellar ataxia type 10 (SCA10) is a relatively
common form of inherited ataxia among the Hispanic populations
in which an unstable expansion of the ATTCT pentanucleotide repeat
in intron 9 of the E46L gene causes the disease by alteration
of E46L transcription through a repeat size-dependent
mechanism. To examine this hypothesis we plan to: 1) Characterize
SCA10 as a clinical entity caused by ATTCT repeat expansion;
2) Examine E46L transcript in patients with SCA10 and
normal subjects; and 3) Investigate E46L protein function. We
are also making an E46L deficient mouse model and
transgenic mice that express expanded ATTCT repeats.
Myotonic Dystrophy
Type 1. Myotonic dystrophy type 1 is the most common adult
form of muscular dystrophy and affects many organs and tissues
other than muscle, including eyes, brain, gastrointestinal tract,
and endocrine system. The disease is caused by an expansion
of an unstable CTG repeat in the 3’ untranslated region of the DMPK gene. We
have been studying the mechanism of repeat instability and the
effect of repeat expansion on the signal transduction system
in myotonic dystrophy type 1 (Supported by The Hunter Research
Fund).
Huntington’s
Disease. Huntington’s disease is one of the most devastating
neurodegenerative disorders. We are researching problems
associated with the end of life in this disease involving both
patients and their families. Our goal is to present resources
and strategies to alleviate these problems (Supported by the
Robert Wood Johnson Foundation.). We are also involved
in a multicenter project to identify genetic modifiers of the
age of onset in Huntington’s disease. To accomplish this
goal, we are collecting sib pairs affected by this disease, and
identify the genetic loci of modifiers by the sib pair analysis
(NIH). We contribute our patient data to the international
Huntington’s disease clinical database (Huntington Study Group)
and participate in a double-blind multicenter placebo-controlled
clinical trial to assess efficacy of tetrabenazine for treatment
of movement disorder in Huntington’s disease.
Friedreich’s
Ataxia. Friedreich’s ataxia is the most common recessive
ataxia caused by a GAA trinucleotide repeat expansion. We
have been developing the rating scale for the translational research
program for this disease as a member of the Cooperative Ataxia
Group (CAG). I was the previous president of the CAG, and
the chair of the Friedreich’s ataxia subcommittee of the CAG. The
proposal for this project has been sent to NINDS for funding. We
are also studying the instability of the GAA repeat in collaboration
with Dr. Sanjay Bidichandani at the University of Oklahoma.
B. Grant
Support (past
five years)
2003-2006 Muscular
Dystrophy Association; Clinical Outcomes in Friedreich’s Ataxia.
2003-2004 Prestwick
Pharmaceuticals; A Randomized Double-Blind, Placebo Controlled
Study of Tetrabenazine for the Treatment of Huntington’s Chorea.
2003-2004 Sealy
Center on Aging Pilot Project Research Program; Myotonic Dystrophy
Type I.
2001-2005 National
Institute of Health (NINDS; 1 RO1 NS41547-01); Pathogenic mechanism
of spinocerebellar ataxia type 10
2000-2002 Hunter
Research Fund
2001 Muscular
Dystrophy Association, Organization of the International Myotonic
Dystrophy Consortium Conference, Kyoto, Japan, October 9-11,
2002 Huntington’s
Disease Center of Excellence
1999 Veteran
Affairs Merit Review
1999 Denver
Fund for Health and Medical Research
1999 Muscular
Dystrophy Association Meeting Grant
1998 Oxnard
Foundation/National Ataxia Foundation
COMMITTEE
RESPONSIBILITIES:
A. National
2002-Pres Robert
Wood Johnson Promoting Excellence in End-of-Life Care HD Workgroup
2001-Pres European
Neuromuscular Center (ENMC) Conference Workshop on Myotonic Dystrophy
2001-Pres Muscle
Study Group (An international consortium for studies of myopathies)
2001-Pres National
Registry of Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy
2001-Pres Patients
and Family Members Member, NIH Scientific Advisory Committee
2001 NIH/NIAMS
Facioscapulohumeral muscular dystrophy R21 Study Section ad
hoc reviewer
2001 The
Muscular Dystrophy Campaign, Cambridge, UK
2001 Association
Française
contre les Myopathies, Paris, France
2000-Pres European
Neuromuscular Center (ENMC) Conference Workshop on Proximal Myotonic
Myopathy
1999-Pres The
Section of Neuromuscular Disorders, American Academy of Neurology
1999-Pres Cerebellar
Ataxia Group (An international consortium for studies of spinocerebellar
ataxia) (Chair, the Friedreich’s Ataxia Committee; member)
1998 Committee
for Guidelines for Huntington's disease DNA testing, American
College of Medical Genetics (member).
1998-2000 NIH/NINDS
Neurological Sciences and Disorders B (NSD-B) Study Section ad hoc reviewer on three occasions
1998-1999 The
Italian Telethon Foundation, Rome, Italy
1997-Pres International
Myotonic Dystrophy Consortium (Consortium founder and member)
1997-2000 Advisory
Panel, U.S. Huntington Disease Genetic Testing
Group
1996 Huntington
Study Group (An international consortium for studies of Huntington's
disease - member)
B. University
of Texas Medical Branch
2004 Judge,
National Student Research Forum 45th Annual Meeting,
Session D Neuroscience. UTMB
and the AMA Foundation.
2004-present Member,
Dean of Medicine Search Committee
2004-present Vice
Chair, Search Committee for Chair of Human Biochemistry and Genetics
2004-present Kempner
Symposium Preparation Committee
2004-present Austin
Fund Raising Committee
2004-present Post
Faculty Research Recruit Committee
2003-present Senior
Fellow, Sealy Center on Aging, Executive Committee
2003-present Member,
Research/Patient Care Facility Executive Committee
2002-2003 Member,
Search Committee for Chair of Otolaryngology, UTMB
2002-2003 Member,
Search Committee for Chair of Anatomy and Neurosciences, UTMB
2002-2003 Member,
Search Committee for Endowed Chair in Cognitive Rehabilitation,
UTMB
2002-present Member-at-Large,
Executive Committee of the Faculty of Medicine, UTMB
2002-present Member,
Faculty Practice Council, UTMB
2002-present Member,
Planning Committee, General Clinical Research Center Imaging
and Body Composition Core, UTMB
2002-2003 Member,
Planning Committee, Clinical and Basic Research Center (CBMRC),
UTMB
2002-present Member,
Medical School Research and Development Plan (MSRDP) Committee,
UTMB
2002-present Member,
UTMB Quality of Care Committee, UTMB
2002-present Member,
Faculty/Staff Campaign Planning Committee, UTMB
2002 Chairman,
Research and Development Committee, VAMC, Houston
2000-2002 Member,
Research and Development Committee, VAMC, Houston (Also
1988-1991, 1993-1996)
1994-2002 Member,
Education Committee, Department of Neurology, Baylor College
of Medicine, Houston
1996-1998 Chairman,
Neurobehavioral Subcommittee, VAMC, Houston
1989-1996 Chairman,
Library Committee, VAMC, Houston
1987-1996 Quality
Assurance Director, Neurology Service, VAMC, Houston
1989-1993 Member,
Institutional Review Board, Baylor College of Medicine, Houston
1986-1989 Member,
Professional Review Organization Committee, VAMC, Houston
1986-1987 Chairman,
Basic Science Subcommittee, VAMC, Houston
1985-1986 Member,
Basic Science Subcommittee, VAMC, Houston
C. Departmental
2002-Pres. Appointment,
Promotion and Tenure Committee
TEACHING
RESPONSIBILITIES AT UTMB:
Direct
medical residents and interns on a daily basis.
MEMBERSHIP
IN SCIENTIFIC SOCIETIES:
American
Neurological Association (by invitation only)
Human
Genome Organization (by invitation only)
American
Academy of Neurology
American
Society of Human Genetics
American
Association for the Advancement of Science
American
Medical Association
Japanese
Association of Neurology
BOARD
CERTIFICATION:
Specialty
Board: American
Board of Psychiatry and Neurology (For Neurology). #20523,
Certified in January, 1980
Certification: ECFMG:
#189 222 3, January 24, 1973
LICENSURE
INFORMATION:
Medical Licenses: Pennsylvania
#35903, 08/20/1975 (Lapsed)
Texas
#E6717, 08/29/1976, exp. 02/05
Japan
#219212, 06/13/1973, no exp. Date
PATENT INFORMATION:
DNA Test for
SCA-10, US Patent Application Number 09/942,336. In progress.
HONORS:
2004 “Promoting
Excellence In End-of Life-Care” certificate presented by the
Huntington’s Disease Peer Workgroup, The Robert Wood Johnson
Foundation, University of Montana.
2002 John
Sealy Chair in Neurology (Endowment)
2000 Plenary
presentation at the 125th Annual Meeting of the American
Neurological Association
1995 Award
for the participation and leadership involved with the planning
and evaluation of education and courses, Baylor College of Medicine
Curriculum Committee
1993 Plenary
presentation at the 43rd Annual Meeting of the American
Society of Human Genetics
1989 Veterans
Administration Directors Award for Professional Leadership
1984 Outstanding
Service Award by the Greater South Texas Chapter of the Myasthenia
Gravis Foundation
1980 Texas
Neurological Society Research Award
ADDITIONAL
INFORMATION:
Hospital
Appointments
2002-
present Active Staff, The University of Texas Medical
Branch Hospitals, Galveston, Texas
1987-2002 Active
Staff, The Methodist Hospital, Houston,
Texas
1981-2002 Staff
Neurologist, VAMC, Houston, Texas
Meetings Organized
1. Scientific
Advisory Committee for the National Registry, Scientific advisor,
Session Chair and presented Session Summary, Rochester, NY, Sept.
22-23, 2003
2. Parkinson
Study Group, 17th Annual Symposia on Etiology, Pathogenesis
and Treatment of Parkinson’s Disease and Other Movement Disorders,
San Francisco, CA, Oct. 19, 2003.
3. UTMB/Baylor
College of Medicine, Alzheimer’s Basic Research Conference, South
Shore Harbor, Texas, November 16, 2002
4. Third
International Myotonic Dystrophy Consortium Conference (IDMC-3),
Kyoto, Japan, October 2001
5. Hunter-Lord
Myotonic Dystrophy Brain Storming Session, Philadelphia, PA,
October 2000
6. Second
International Myotonic Dystrophy Consortium Conference (IDMC-2),
Research Triangle, NC, April 1999
7. Myotonic
Dystrophy Workshop, IX International Congress of Neuromuscular
Diseases, Adelaide, Australia, August 1998
8. First
International Myotonic Dystrophy Consortium Workshop (IDMC-1),
Paris, France, June 1997
9. Huntington's
Disease Symposium, Houston, Texas, February 1996
Scientific
Research Consortium Membership:
1. Robert
Wood Johnson Promoting Excellence in End-of-Life Care HD Workgroup
(2002)
2. European
Neuromuscular Center (ENMC) Conference Workshop on Myotonic Dystrophy
(since 2001)
3. Muscle
Study Group (An international consortium for studies of myopathies;
since 2001)
4. National
Registry of Myotonic Dystrophy and Facioscapulohumeral Muscular
Dystrophy
5. Patients
and Family Members (NIH-funded project) (member of the Scientific
Advisory Committee,
since 2001)
6. European
Neuromuscular Center (ENMC) Conference Workshop on Proximal Myotonic Myopathy
(since 2000)
7. The
Section of Neuromuscular Disorders, American Academy of Neurology
(member since 1999)
8. International
Myotonic Dystrophy Consortium (Consortium founder; member since
1997)
9. Huntington
Study Group (An international consortium for studies of Huntington's
disease) (member, since 1996)
10. Cerebellar
Ataxia Group (An international consortium for studies of spinocerebellar
ataxia) (Chair, the Friedreich’s Ataxia Committee; member, since
1999)
11. Advisory
Panel, U.S. Huntington Disease Genetic Testing
Group (1997-2000)
12. Committee
for Guidelines for Huntington's disease DNA testing, American
College of Medical Genetics (member, 1998)
Experience
In Multicenter Clinical Studies:
1. A
randomized double-blind, placebo-controlled study of Tetrabenazine
for the treatment of Huntington’s Chorea, Protocol number TBZ
103,004; Prestwick Pharmaceuticals and the Huntington’s Study
Group; site investigator 2003 2004.
2. Phase
II trial of idebenone in Friedreich’s ataxia, a multicenter study
organized by NIH/NINDS and the University of Pennsylvania (Steering Committee
member since 2001)
3. Co-enzyme
Q10 and remacemide: evaluation in Huntington’s Disease (CARE-HD;
NIH 5 RO1 NS35284; site investigator; 1996-2001)
4. Pilot
Huntington at risk observational study (PHAROS; funding application
NIH RO1-HG
02449-01 submitted; site investigator; since 2000)
5. Pilot
study of minocycline in Huntington’s disease (non-sponsored open
trial; co-investigator, since 2001).
Invited
Lectures
1. “Management
of myasthenia gravis.” Myasthenia Gravis Foundation, Greater
South Texas Chapter. Houston, Texas. May 1984.
2. “Molecular
diagnosis of myotonic dystrophy.” Muscular Dystrophy Association,
Houston Chapter. Houston, Texas. May 1987.
3. “A
molecular mechanism of anticipation in myotonic dystrophy.” Department
of Internal Medicine, Osaka Medical College. Osaka,
Japan. August 1993
4. “Instability
of the CTG repeat in myotonic dystrophy.” Department of
Neurology, Tokai University School of Medicine. Kanagawa, Japan. July 1994.
5. “Characteristics
of expanded CTG repeats in myotonic dystrophy.” Department
of Geriatric Medicine, Osaka University School of Medicine. Osaka,
Japan. July 1994.
6. “Presymptomatic
diagnosis of Huntington's disease.” Huntington's Disease
Patient Support Group of Houston. Houston, Texas. September 1994.
7. “Genotype-phenotype
correlation in myotonic dystrophy - monozygotic twins with myotonic
dystrophy.” Muscular Dystrophy Association Genetic Workshop
on Myotonic Dystrophy. Montreal, Canada. October 1994.
8. “Characteristics
of the CTG repeat instability in myotonic dystrophy.” Unitat
de Genetica Molecular. Hospital de la Santa Creu i Sant
Pau. Barcelona, Spain. October 1994.
9. “Characteristics
of the (CTG)n repeat instability in myotonic dystrophy.” XXIII
Congresso National, A.N.M.I.R.S. Rome, Italy. October 1994.
10. “Characteristics
of the (CTG)n repeat length instability in cloned DM lymphoblastoid
cell lines in culture.” Muscular Dystrophy Association
Genetic Workshop on Myotonic Dystrophy. Minneapolis, Minnesota. October 1995.
11. “Myotonic
dystrophy: clinical and molecular genetic findings.” Current
Neurology. Houston, TX, November 1995.
12. “Disclosure
of the (CAG)n repeat size.” Huntington Study Group. Atlanta, GA, December 1995
13. “Advances
of clinical research in Huntington's disease.” The Huntington's
Disease Genetic Testing Workshop at the Annual Meeting of American
Society of Human Genetics, San Francisco, October 1996.
14. “Instability
of CTG repeat in myotonic dystrophy.” University of Rochester
Medical School. Rochester, NY, January 1997.
15. “The
mechanisms involved in CTG repeat instability in myotonic dystrophy.” INSERM
UR 383 "Génétique, Chromosome et Cancer," Hôpital Necker ‑ Enfants
Malades. Paris, France, February 1997.
16. “Update
of clinical research in Huntington's disease.” The Huntington's
Disease Genetic Testing Workshop at the Annual Meeting of American
Society of Human Genetics, San Francisco, October 1997.
17. “Huntington's
disease. Current Neurology.” Houston, TX, November 1997.
18. “Huntington's
disease: research, treatment and alternative.” The Huntington
Disease Society of America (HDSA), 7th Texas Chapter Meeting. Dallas,
TX, September 1998.
19. “Update
of Huntington's disease. Current Neurology.” Houston, TX, November 1998.
20. “Genetics
of Tourette Syndrome.” Tourette Syndrome and Related Neurobehavioral
Disorders for Physicians. Houston, TX, January 1999.
21. “Treatment
of Huntington's disease.” Simposio: Enfermedad de Huntington:
Perspectivas para el Inicio del Milenio. Mexico City, Mexico, March 1999.
22. “An
expansion bias in the instability of the myotonic dystrophy CTG
repeat in patient-derived limphoblastoid cell lines.” The
2nd International Myotonic Dystrophy Conference, Research Triangle,
NC, April 1999.
23. “Genetics
of Gilles de la Tourette Syndrome.” Tourette Syndrome Association
Symposium, Houston, TX, January 2001.
24. “Myotonic
dystrophy and related disorders.” The National University
of Costa Rica, San Jose, Costa Rica, February 2001.
25. “Spinocerebellar
ataxia type 10.” The National Ataxia Foundation. Minneapolis, MN, April 2001.
26. “Identification
of the mutation for spinocerebellar ataxia type 10.” Symposium,
the 42nd Japanese Neurologica Society, Tokyo, Japan,
May 2001.
27. “Unstable
short tandem repeats and neurological diseases.” Osaka Medical College, Takatsuki, Japan, May 2001.
28. “Pathogenesis
of myotonic dystrophy.” 99th Workshop of the European
Neuro-Muscular Center. Myotonic Dystrophy: Present Management,
Future Therapy, Naarden, The Netherlands, November 2001.
29. “Spinocerebellar
ataxias.” The University of Texas Medical Branch, Galveston,
Texas, January 2002.
30. “Autosomal
dominant ataxias.” The 2nd Sino-US Medical Symposium,
Shanghai, China, April 2002.
31. “Expanded
ATTCT repeats in spinocerebellar ataxia type 10.” Dept. of Anatomy
and Neuroscience, The University of Texas Medical Branch, Galveston,
Texas, September 2002.
32. “Autosomal
dominant cerebellar ataxias.” 2nd Sino-US Medical
Symposium, Shanghai, China, October 2002.
33. “Spinocerebellar
ataxia type 10.” The Keio Medical Society. Keio University School
of Medicine, Tokyo, Japan, November 2002.
34. “Spinocerebellar
ataxia type 10.” Keio University School of Medicine,
Tokyo, Japan, December 2002.
35. “The
Genetics of Dementia” Titus Harris Society 43rd Annual
Meeting, Galveston, TX, March 2003.
36. Ashizawa
T. Towards treatments for myotonic dystrophy. The 4th International
Myotonic Dystrophy Consortium Meeting, April 2003, Glasgow, UK.
37. “CTG
Repeats in Myotonic Dystrophy” Dept. of Human Biological Chemistry & Genetics,
University of Texas Medical Branch, Galveston, TX, May 2003.
38. “New
Changes in Neurology Residency in the United States” Japan Neurology
Society, Yokohama, Japan, May 2003.
39. “Molecular
Genetics of Myotonic Dystrophy” Grand Rounds, Kurume University,
Kurume , Japan, May 2003.
40. “Clinical
Presentation of P/Q-Type calcium Channel Dysfunction in the Peripheral
and Central Nervous Systems” Muscle Study Group, Annual Planning
Meeting, Beaver Hollow, NY, October 2003.
41. “Instability
of Expanded CAG/CAA Repeats in Spinocerebellar Ataxia Type 17” 17th Annual
Symposia on Etiology, Pathogenesis and Treatment of Parkinson’s
Disease and Other Movement Disorders, San Francisco, CA, October
2003..
42. “Scientific
Advances and their Relevance to Therapy” 2nd International
Workshop of ENMC Myotonic Dystrophy Management and Therapy Consortium,
Naarden, Netherlands, February 2004.
43. “Spinocerebellar
Ataxia Type 10; Update” 4th International Conference
on Unstable Microsatellites and Human Disease, Banff, Canada,
February 2004.
Administrative
Experience:
1. Chairman,
Department of Neurology, The University of Texas Medical Branch,
2002-present
2. Director,
HDSA Huntington’s Disease Center of Excellence, Baylor College
of Medicine, 2002
3. Director,
Huntington’s Disease Clinic, Baylor College of Medicine, 1997-2002
4. Director,
The Ataxia Clinic, Baylor College of Medicine, 1997-2002
5. Director
of Neurology Residency and Student Programs, Department of Neurology,
6. Baylor
College of Medicine, Houston, 1994-1996
7. Assistant
Chief of Neurology Service and Deputy Executive of Neurology
Care Line, VAMC, Houston, 1985-2002
8. Acting
Chief, Neurology Service, VAMC, Houston, 1/15/88-6/30/88
Reviewer
for Journals
1. American
Journal of Human Genetics
2. American
Journal of Medical Genetics
3. Annals
of Neurology
4. Archives
of Neurology
5. Clinical
Immunology and Immunopathology
6. European
Journal of Human Genetics
7. Genomics
8. International
J. of Developmental Neuroscience
9. Human
Molecular Genetics
10. JAMA
(Journal of American Medical Association)
11. Journal
of Neurological Science
12. Journal
of Neurogenetics
13. Nature
14. Neurogenetics
15. Neurology
16. Proceedings
of National Academy of Science, U.S.A.
Editorial
Board Membership
2003-Present Neurology
2003-Present International
J. of Developmental Neuroscience
Educational
Activities
1994-1996 Student/Resident
Program Director, Department of Neurology, Baylor College of
Medicine, Houston, Texas
Graduate
Students
- Committee
Member for Ralf Krahe, Ph.D., 1991-1996, Department of Molecular
Genetics, MD Anderson Cancer Center, Houston, Texas
- Committee
Member for Nia Spring, Ph.D., 1996-2001, Department of Molecular
Genetics, MD Anderson Cancer Center, Houston, Texas
- Committee
Member for Thomas Barber, Ph.D., 1993, Department of Molecular
and Human Genetics, Baylor College of Medicine, Houston, Texas
- Committee
Member for Pangela Papagiorgio, M.S., 2001, Department of Molecular
Genetics, MD Anderson Cancer Center, Houston,
Texas
- Committee
Member for Eliana Romero, B.S., 2000-present, Department of
Molecular and Human Genetics, Baylor College of Medicine, Houston,
Texas
- Mentor
for June Yawtak, B.S., 2003, Summer Rotation in the Neuroscience
Graduate Program, Graduate School of Biomedical Sciences, The University
of Texas Medical Branch, Galveston, Texas
- Mentor
for Misti Caudle-White, B.S., 2004, Rotation in the Neuroscience
Graduate Program, Graduate School of Biomedical Sciences, The University
of Texas Medical Branch, Galveston, Texas
- Mentor
for William J Reddig, B.S., 2004, Rotation in the Neuroscience
Graduate Program, Graduate School of Biomedical Sciences, The University
of Texas Medical Branch, Galveston, Texas
Postdoctoral
Fellows
Gyoergie Horvath, M.D., 1996-1998
William W. Wang, M.D., Ph.D., 1995-1997
Tohru Matsuura, M.D., 1998-2002
Shinichiro Nagamitsu, M.D., Ph.D., 1998-2001
Eng King Tan, M.D., 2000
Yu-Jiang Li, M.D., Ph.D., 2001-2002
Rui Gao, M.D., 2001-present
Ryoko Kozuma, 2002-2003
Waragai, Masaaki, 2002-present
Visiting
Scientists
Rajith
N. de Silva, M.D. Visiting Assistant Professor at Baylor College
of Medicine, Houston, TX (04/01/97 - 10/31/97), current position: Private practice (Consultant), London,
UK.
Astrid
Rasmussen, M.D., Ph.D. Visiting Scientist at Baylor College of
Medicine, Houston, TX (05/01/00 - 05/21/00); current position:
Associate Professor, The National Institute of Neurology and
Neurosurgery, Mexico City, Mexico.
Alberto
L. Rosa, M.D., Ph.D. Visiting Associate Professor at Baylor College
of Medicine, Houston, TX (11/01/00 - 10/31/01); current position:
Associate Professor, University of Cordoba, Cordoba, Argentina.
Yume
Suzuki, M.D. Visiting Assistant Professor at Baylor College of
Medicine, Houston, TX (04/01/01 - 03/31/02), current position:
Associate Professor, Yokohama City Medical University, Yokohama, Japan.
Daisuke
Furutama, M.D. Visiting Scientist, University of Texas
Medical Branch, Galveston, TX (03/24/03 05/09/03), current
position: Faculty Member, The First Department of Internal
Medicine, Osaka Medical College, Osaka, Japan.
PUBLISHED
A. Peer-Reviewed
Journals
1. Ashizawa
T, Patten BM, Jankovic J. Meige's syndrome. South Med J. 1980;73:863-866
2. Sabina
RL, Swain JL, Patten BM, O'Brien W, Ashizawa T, Holmes EW. Disruption
of the purine nucleotide cycle: A potential explanation for muscle
dysfunction in myoadenylate deaminase deficiency. J Clin Investigat 1980;66:1419-1423
3. Ashizawa
T, Patten BM, Sabina RL. Purine nucleotide metabolism in myoadenylate
deaminase deficiency. Trans Am Neurol Assoc 1980;105:488-491
4. Appel
SH, Blosser JC, McManaman JL, Ashizawa T, Elias SB. The effects
of carbamylcholine, calcium and cyclic nucleotides on acetylcholine
receptor synthesis in cultured myotubes. Ann NY Acad Sci 1981;377:189-196
5. Ashizawa
T, Elias SB, Appel SH. The interaction of myasthenic globulins
and cholinergic agonists on acetylcholine receptors of rat myotubes. Ann
Neurol 1982;11:22-27
6. Appel
SH, Blosser JC, McManaman JL, Ashizawa T. Acetylcholine receptor
turnover in myasthenia gravis. 1982; Am J Physiol 243:E31-E36
7. Ashizawa
T, Butler IJ, Harati Y, Roongta S. A dominantly inherited syndrome
with continuous motor neuron discharges. Ann Neurol 1983;13:285-290
8. Ashizawa
T, Appel SH. Complement-dependent myotube lysis mediated by myasthenic
immunoglobulins. Neurology 1985;35:1748-1753
9. Rolak
L, Ashizawa T. The hot bath test in multiple sclerosis. Comparison
with visual evoked responses and oligoclonal bands. Acta Neurol
Scand 1985;72:65-67
10. Diaz-Arrastia
R, Ashizawa T, Appel SH. Endogenous modulator of ligand binding
to the muscarinic acetylcholine receptor. J Neurochem 1985;44:622-628
11. Kelly
GR, Ashizawa T, Gyorkey F. Herpes simplex encephalitis: A case
with dysplastic plasma cell infiltration. Arch Path Lab Med 1986;110:82-85
12. Levy
JD, Cottingham KL, Campbell RJ, Moore GK, Gyorkey F, Ashizawa
T, Goldman AM: Progressive multifocal leukoencephalopathy
and magnetic resonance imaging. Ann Neurol 1986;19:399-401
13. Ashizawa
T, Rolak LA, Hines M. Spastic pure motor monoparesis. Ann
Neurol 1986;20:638-641
14. Ashizawa
T, Appel SH. Complement-dependent pathogenicity of myasthenic
immunoglobulins: An in vitro study. Ann NY Acad Sci 1988;505:708-711
15. Stewart
SS, Dudley AW, Ashizawa T, Goldberg J, Lidsky MD. Cerebral vasculitis
in relapsing polychondritis. Neurology 1988;38:150-152
16. Perryman
B, Hejtmancik JF, Ashizawa T, Armstrong RM, Epstein HF. NcoI
and TaqI RFLPs for human M creatine kinase. Nucl Acid Res 1988;16:8744
17. Griggs
RC, Wood DS. The Working Group on the Molecular Defect in Myotonic
Dystrophy: Criteria for establishing the validity of genetic
recombination in myotonic dystrophy. Neurology 1989;39:420-421
18. Oshima
M, Ashizawa T, Pollack MS, Atassi MZ. Autoimmune T-cell recognition
of human acetylcholine receptor: The sites of T-cell recognition
in myasthenia gravis on the extracellular part of the α-subunit. Eur
J Immunol 1990;20:2503-2569
19. Ashizawa
T, Oshima M, Ruan K-H, Atassi MZ. Autoimmune recognition profile
of the α-chain of human acetylcholine receptor in myasthenia
gravis. Adv Exp Med Biol 1991;303:255-261
20. Ashizawa
T, Hejtmancik JF, Liu J, Perryman MB, Epstein HF, Koch DD. Diagnostic
values of ophthalmologic findings in myotonic dystrophy: comparison
with risks calculated by haplotype analysis of closely linked
RFLP's. Am J Med Genet 1992;42:55-60
21. Rolak
LA, Rutecki P, Ashizawa T, Harati Y. Clinical features of Todd's
post-epileptic paralysis. J Neurol Neurosurg Psychiat 1992;55:63-64
22. Fu
Y-H, Pizzuti A, Fenwick R, King J, Rajnarayan S, Dunne PW, Dubel
J, Nasser GA, Ashizawa T, de Jong P, Wieringa B, Korneluk R,
Perryman MB, Epstein HF, Caskey CT. An unstable triplet repeat
in a gene related to myotonic muscular dystrophy. Science 1992;225:1256-1258
23. Dubel
JR, Epstein HF, Perryman MB, Armstrong RM, Ashizawa T. Phenotypic
expression in monozygotic twins with myotonic dystrophy. Neurology 1992;42:1815-1817
24. Atassi
MZ, Ruan K-H, Jinnai K, Oshima M, Ashizawa T. Epitope-specific
suppression of antibody response in experimental autoimmune myasthenia
gravis by an m-PEG conjugate of a myasthenogenic synthetic peptide. Proc
Natl Acad Sci 1992;89:5852-5856
25. Ashizawa
T, Ruan K-H, Atassi MZ. Profile of the regions on the α-chain
of human acetylcholine receptor recognized by autoantibodies
in myasthenia gravis. Mol. Immunol. 1992;29:1507-1514
26. Ashizawa
T, Dunne CJ, Dubel JR, Perryman MB, Epstein HF, Boerwinkle E,
Hejtmancik JF. Anticipation in myotonic dystrophy: I. statistical
verification based on clinical and haplotype findings. Neurology 1992;42:1871-1877
27. Buxton
J, Shelbourne P, Davies J, Jones C, Perryman MB, Ashizawa T,
Butler R, Brook D, Shaw D, de Jong P, Markham A, Williamson R,
Johnson K. Characterization of a YAC and cosmid contig containing
markers tightly linked to the myotonic dystrophy locus on chromosome
19. 1992;Genomics 13:526-531
28. Ashizawa
T, Dubel JR, Dunne CJ, Fu Y-H, Pizzuti A, Caskey CT, Boerwinkle
E, Perryman MB, Epstein HF, Hejtmancik JF. Anticipation in myotonic
dystrophy: II. Complex relationships between clinical findings
and structure of the GCT repeat. Neurology 1992;42:1877-1883
29. Dunne
PW, Wang S-W, Ashizawa T, Perryman MB, Epstein H.F. cDNA
surveying of specific tissue expression of human chromosome 19
sequences. Genomics 1992;14:263-269
30. Fu
Y-H, Friedman DL, Richards S, Pearlman JA, Gibbs RA, Pizzuti
A, Ashizawa T, Perryman MB, Scarlato G, Fenwick RG, Jr, Caskey
CT. Decreased expression of myotonin-protein kinase messenger
RNA and protein in adult form of myotonic dystrophy. Science 1993;260:235-238
31. Ashizawa
T, Dubel JR, Harati Y. Somatic instability of GCT repeat in myotonic
dystrophy. Neurology 1993;43:2674-2678
32. Ashizawa
T, Anvret M, Baiget M, Barceló JM, Brunner H, Cobo AM, Dallapiccola
B, Fenwick RG Jr, Grandell U, Harley H, Junien C, Koch MC, Korneluk
RG, Lavedan C, Miki T, Mulley JC, López de Munain A, Novelli
G, Roses AD, Seltzer WK, Shaw DJ, Smeets H, Sutherland GR, Yamagata
H, Harper PS. Characteristics of intergenerational contractions
of the CTG repeat in myotonic dystrophy. Am J Hum Genet 1994;54:414-423
33. Ashizawa
T, Dunne PW, Ward PA, Seltzer WK, Richards CS. Effects of the
sex of myotonic dystrophy patients on the unstable triplet repeat
in their affected offspring. Neurology 1994;44:120-122
34. Atassi
MZ, Mulac-Jericevic B, Ashizawa T. Mapping of the polypeptide
chain organization of the main extracellular domain of the α-subunit
in membrane-bound acetylcholine receptor by anti-peptide antibodies
spanning the entire domain. Adv Exp Med Biol 1994;347:221-228
35. Ashizawa
T, Wong L-J, Richards CS, Caskey CT, Jankovic J. The CAG repeat
size and clinical presentation in Huntington's disease. Neurology 1994;44:1137-1143
36. Jinnai
K, Ashizawa T, Atassi MZ. Analysis of exposed regions of the
main extracellular domain of acetylcholine receptor α-subunit
by antibody binding profiles. J Prot Chem 1994;13:715-722
37. Jankovic
J, Ashizawa T. Tourettism associated with Huntington's disease. Movement
Disorders 1995;10:103-105
38. Wong
L-J, Ashizawa T, Monckton DG, Caskey CT, Richards SC. Somatic
heterogeneity of the CTG repeat in myotonic dystrophy is age
and size dependent. Am J Hum Genet 1995;56:114-122
39. Monckton
DG, Wong L-JC, Ashizawa T, Caskey CT. Somatic mosaicism, germline
expansions, germline reversions and intergenerational reductions
in myotonic dystrophy males:small pool PCR analyses. Hum Mol
Genet 1995;4:1-8
40. Krahe
R, Eckhart M, Ogunniyi AO, Osuntokun BO, Siciliano MJ, Ashizawa
T. de novo myotonic dystrophy mutation in a Nigerian kindred. Am
J Hum Genet 1995;65:1067-1074
41. Jankovic
J, Beach J, Ashizawa T. Emotional and functional impact of DNA
testing on patients with symptoms of Huntington's disease. Am
J Med Genet 1995;32:516-518
42. Krahe
R, Ashizawa T, Abbruzzese C, Roeder E, Carango P, Giacanelli
M, Funanage VL, Siciliano MJ. Effect of myotonic dystrophy trinucleotide
repeat expansion on DMPK transcription and processing. Genomics 1995;28:1-14
43. Tokgozoglu
LS, Ashizawa T, Pacifico A, Epstein H, Zoghbi WA. Cardiac involvement
in a large kindred with myotonic dystrophy:quantitative assessment
and relation to expansion of CTG repeats. JAMA 1995;274:813-819
44. Ashizawa
T, Monckton DG, Vaishnav S, Patel BJ, Voskova A, Caskey CT. Instability
of the expanded (CTG)n repeats in the myotonin protein kinase
gene in cultured lymphoblastoid cell lines from patients with
myotonic dystrophy. Genomics 1996;36:47‑53
45. Abbruzzese
C, Krahe R, Liguori M, Tessarolo D, Siciliano MJ, Ashizawa T,
Giacanelli M. Myotonic dystrophy phenotype without expansion
of (CTG)n repeat, distinct from proximal myotonic myopathy (PROMM). J
Neurol 1996;243:715-721
46. Ashizawa
T, Jankovic J. Cervical dystonia as the initial presentation
of Huntington's disease. Movement Disorders 1996;11:457-459
47. Petronis
A, Heng HHQ, Tatuch Y, Shi X-M, Tsui,L-C, Ashizawa T, Surh LC,
Kennedy JL. Direct detection of expanded trinucleotide repeats
using DNA hybridization techniques. Am J
Med
Genet 1996;67:85-91
48. Alford
RL, Ashizawa T, Jankovic J, Caskey CT, Richards CS. Spontaneous
expansion of a paternal CAG repeat allele resulting in sporadic
Huntington's disease. Am J Med Genet 1996;66:281-286
49. The
Huntington Study Group: Unified Huntington Disease Rating Scale. Movement
Disorders 1996;11(2):136-142.
49a. Ashizawa, T., Jankovic, J. Cervical dystonia as the initial presentation
of Huntington’s disease. Movement Disorders
1996;11(4):457-459.
50. Zhuchenko
O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, Amos C, Dobyns
WB, Subramony SH, Zoghbi HY, Lee CC. Autosomal dominant cerebellar
ataxia (SCA6) associated with small polyglutamine expansions
in the a1A-voltage-dependent calcium channel. Nature Genet 1997;15:62-69
51. Bidichandani
SI, Ashizawa T, Patel PI. Atypical Friedreich’s ataxia caused
by compound heterozygosity for a novel missense mutation and
the GAA triplet-repeat expansion. Am J Hum Genet 1997;60:1251-1256
52. Wong
L-JC, Ashizawa T. Postzygotic instability of the CTG repeat in
congenital myotonic dystrophy. Am J Hum Genet 1997;61:1445-1448
53. Nance
MA and the US Huntington Disease Genetic Testing Group: Genetic
testing of children at risk for Huntington disease. Neurology 1997;49:1048-1053
(Listed as an Advisory Board member in the coauthor list)
54. Bidichandani
SI, Ashizawa T, Patel P. The GAA triplet repeat expansion in
Friedreich’s ataxia interferes with transcription and may be
associated with an unusual DNA structure. Am J Hum Genet 1998;62:111-121
55. de
Silva RN, Stockton DW, Keats B, Justice CM, Richards CS, Ashizawa
T. Delayed diagnosis of Friedreich's ataxia due to coexisting
recessive deaf/blind syndrome. Neurology 1998;50:1924-1925
56. Nance
MA, Seltzer W, Ashizawa T, Bennett R, McIntosh N, Myers RH, Potter
NT, Shea DK. Laboratory guidelines for Huntington disease genetic
testing: The American College of Medical Genetics/American Society
of Human Genetics Huntington Disease Working Group. Am
J Hum Genet 1998;62:1243-1247
57. Benton
CS, de Silva R, Rutledge SL, Bohlega S, Ashizawa T, Zoghbi HY.
Molecular and clinical studies in SCA7 define a broad clinical
spectrum and the infantile phenotype. Neurology 1998;51:1081-1086
58. Wang
WW, Khajavi M, Patel BJ, Jankovic J, Ashizawa T. The G209A mutation
in the a-synuclein gene is not detected
in familial cases with Parkinson's disease of non-Greek/Italian
populations. Arch Neurol 1998;55:1521‑1523
59. Gourdon
G, Junien C, Ashizawa T. Workshop report: AFM/MDA 1st International
Myotonic Dystrophy Consortium Conference, 30 June-1 July 1997, Paris, France. Neuromusc Disord 1998;8:432-437
60. Matsuura
T, Achari M, Khajavi M, Bachinski LL, Zoghbi HY, Ashizawa T.
Mapping of the gene for a novel spinocerebellar ataxia with pure
cerebellar signs and epilepsy. Ann Neurol 1999;45:
407-411
61. Monckton
DG, Cayuela ML, Gould FK, Brock GJR, de Silva R, Ashizawa T:
Massive (CAG)n DNA repeat expansions in the sperm of spinocerebellar
ataxia type 7 males. Hum Mol Genet 1999;8:2473‑2478
62. Bidichandani
SI, Purandare SM, Taylor EE, Gumin G, Machkhas H, Harati Y, Gibbs
RA, Ashizawa T, Patel PI: Somatic sequence variation at the Friedreich
ataxia locus includes complete contraction of the expanded GAA
triplet repeat, significant length variation in serially passaged
lymphoblasts, and enhanced mutagenesis in the flanking sequence. Hum
Mol Genet 1999;8:2425‑2436
63. Burgess
DL, Matsuura T, Ashizawa T, Noebels JL: Genetic localization
of the Ca2+ channel gene CACNG2 near SCA10 on chromosome 22q13. Epilepsia 2000;41:24‑27
64. Costanzi-Porrini
S, Tessarolo D, Abbruzzese C, Liguori M, Ashizawa T, Giacanelli
M: An interrupted 34-CAG-repeat SCA2 allele in patients with
sporadic spinocerebellar ataxia. Neurology 2000;54:491-493
65. Deitiker
P, Ashizawa T, Atassi MZ. Antigen mimicry in autoimmune disease.
Can immune responses to microbial antigens that mimic acetylcholine
receptor act as initial triggers of myasthenia gravis? Hum
Immunol 2000;61:255-65
66. Tan
EK, Matsuura T, Nagamitsu S, Khajavi M, Jankovic J, Ashizawa
T: Polymorphism of NACP-Rep 1 in Parkinson’s disease: An etiologic
link with essential tremor? Neurology 2000;54:1195-1198
67. The
International Myotonic Dystrophy Consortium (IDMC): New nomenclature
for myotonic dystrophies and DNA testing guidelines for myotonic
dystrophy type 1 (DM1). Neurology 2000;54:1218-1221 (The
corresponding author: Ashizawa T)
68. Swoboda
KJ, Soong B, McKenna C, Brunt ER, Litt M, Bale JF Jr, Ashizawa
T, Bennett LB, Bowcock AM, Roach ES, Gerson D, Matsuura T, Heydemann
PT, Nespeca MP, Jankovic J, Leppert M, Ptacek LJ. Paroxysmal
kinesigenic dyskinesia and infantile convulsions: Clinical and
linkage studies. Neurology 2000;55:224-230
69. Petronis
A, Vincent JB, Surh LC, Ashizawa T, Kennedy JL. Polyglutamine-containing
proteins in schizophrenia: an effect of lymphoblastoid cells? Mol
Psychiatry 2000;5:234-236
70. Nakayashiki
N, Oshima M, Deitiker PR, Ashizawa T, Atassi MZ. Suppression
of experimental myasthenia gravis by monoclonal antibodies against
MHC peptide region involved in presentation of a pathogenic T-cell
epitope. J Neuroimmunol 2000;105:131-144
71. Tan
E-K, Nagamitsu S, Khajavi M, Thornby A, Jankovic J, Ashizawa
T: Variability and Validity of Polymorphism Association Studies
in Parkinson’s Disease. Neurology 2000;55:533-538
72. | 
